Immunotherapy
AssigneeCelldex Therapeutics, Inc.
InventorsJonathan Robert Lamb, Gerard Francis Hoyne
Life of this patent
Estimating the term…
Abstract
A method is provided for enhancing the reactivity of a T cell toward a tumour cell which method comprises: (a) isolating a T cell which is a tumour infiltrating lymphocyte (TIL) from a patient having said tumour cell present in their body; (b) introducing a nucleic acid sequence into the TIL, which sequence is capable of inhibiting or preventing expression of an endogenous Notch ligand in the TIL; and (c) re-introducing the transfected TIL into the patient; wherein the T cell comprises a T cell receptor specific for a tumour antigen expressed by the tumour cell.
Claims47
A method for enhancing the reactivity of a T cell toward a tumour cell comprising the steps of:
- (a) isolating the T cell from a patient, wherein the tumour cell is present in said patient;
- (b) exposing the T cell to an agent, wherein the agent is capable of reducing or preventing expression or interaction of an endogenous Notch or Notch ligand in the T cell;
- and
- (c) re-introducing the T-cell into the patient;
- wherein the T cell comprises a T cell receptor specific for a tumour antigen expressed by the tumour cell.
A method for enhancing the reactivity of a T cell toward a tumour cell comprising the steps of:
- (a) isolating an antigen presenting cell (APC) from a tumour present in a patient;
- (b) exposing the APC to an agent, wherein the agent is capable of reducing or preventing expression or interaction of an endogenous Notch or Notch ligand in the T cell when the T cell is contacted with the APC;
- and
- (c) re-introducing the APC into the patient.
A method for enhancing the reactivity of a T cell toward a tumour cell comprising the steps of:
- (a) isolating a tumour cell from a tumour present in a patient;
- (b) exposing the tumour cell to an agent, wherein the agent is capable of reducing or preventing expression or interaction of an endogenous Notch or Notch ligand in the T cell when the T cell is contacted with the tumour cell;
- and
- (c) re-introducing the tumour cell into the patient.
A method for enhancing the reactivity of a T cell toward a tumour cell comprising exposing the T cell to an agent which is capable of reducing or preventing expression, interaction or processing of an endogenous Notch or Notch ligand in the T cell.
A method for enhancing the reactivity of a T cell toward a tumour cell comprising exposing the tumour cell to an agent which is capable of reducing or preventing expression, interaction or processing of an endogenous Notch or Notch ligand in the T cell when the T cell is contacted with the tumour cell.
A method of vaccinating a patient against a tumour comprising administering an agent which is capable of reducing or preventing interaction, expression or processing of Notch or a Notch ligand.
A method of vaccinating a patient against a tumour comprising the steps of:
- (a) administering a tumour antigen expressed by the tumour to a patient;
- and
- (b) exposing an APC present in the patient to an agent, wherein the agent is capable of reducing or preventing interaction, expression or processing of Notch or a Notch ligand in a T cell.
A transgenic animal or cell line capable of expressing Notch, Notch ligand or an inhibitor or enhancer of Notch-Notch ligand interactions.
An anti-tumour vaccine or immunogenic composition comprising an agent which is capable of reducing or preventing interaction, expression or processing of Notch or a Notch ligand.
An anti-tumour vaccine or immunogenic composition comprising a tumour antigen and an agent which is capable of reducing or preventing interaction, expression or processing of Notch or a Notch ligand.
Dependencies are inferred from the claim text.